Literature DB >> 11391715

Molecular characteristics of pediatric patients with sickle cell anemia and stroke.

S A Sarnaik1, S K Ballas.   

Abstract

Cerebrovascular accidents (CVA) are serious complications of sickle cell anemia (SS) in children. Factors that predispose children to this complication are not well established. In an effort to elucidate the risk factors associated with CVA in SS, we have determined the alpha-globin genotype and the beta(S) haplotype of children with this complication. Among 700 children with SS followed at Children's Hospital of Michigan, 41 (6%) are on chronic transfusions because of stroke due to cerebral infarction. The mean age of patients with CVA at the time of stroke was 5.6 +/- 3.2 years (mean +/- SD). The male/female ratio was 2/3. Only 8 of 41 patients (19.5%) had one alpha-gene deletion, compared to the reported prevalence of 30% in African-Americans. None of the patients had two alpha-gene deletions, and two (5%) had five alpha-genes. These findings are different than those in our adult patients with SS, where the prevalence of -alpha/-alpha and alphaalphaalpha/alphaalpha is 4% and <2%, respectively. Ten different beta(S)-haplotypes were detected in the patients studied. The majority of the patients (31%) were doubly heterozygous for the Ben/CAR haplotypes followed by Ben/Ben, Ben/Sen, and CAR/CAR haplotypes, respectively. The prevalence of these haplotypes, with the exception of the CAR/CAR haplotype, was higher in females than males. All the patients with CAR/CAR haplotype were males, had four alpha-genes, and ranked third in prevalence. Three patients were heterozygous for the Cameron haplotype. The Cameron and atypical haplotypes were more prevalent than reported in patients with SS at large. The data suggest that CVA in children seems to occur more frequently in females and in patients with certain beta(S) haplotype. alpha-Gene deletion seems to offer a protective effect against this complication. Neonates with four or more alpha-genes whose beta(S) haplotype is Ben/CAR, atypical, or CAR/CAR seem to be at a higher risk for CAV than other patients. A prospective study on a larger group of patients with or without CVA may clarify this issue. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391715     DOI: 10.1002/ajh.1103

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

Review 1.  New advances in identifying genetic anomalies in stroke-prone probands.

Authors:  James F Meschia; Bradford B Worrall
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

2.  New advances in identifying genetic anomalies in stroke-prone probands.

Authors:  James F Meschia; Bradford B Worrall
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

Review 3.  Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities.

Authors:  Sharada A Sarnaik
Journal:  Pediatr Radiol       Date:  2005-02-10

4.  Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway.

Authors:  Vikki G Nolan; Adeboye Adewoye; Clinton Baldwin; Ling Wang; Qianli Ma; Diego F Wyszynski; John J Farrell; Paola Sebastiani; Lindsay A Farrer; Martin H Steinberg
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

5.  Acute chest syndrome is associated with single nucleotide polymorphism-defined beta globin cluster haplotype in children with sickle cell anaemia.

Authors:  Christopher J Bean; Sheree L Boulet; Genyan Yang; Amanda B Payne; Nafisa Ghaji; Meredith E Pyle; W Craig Hooper; Pallav Bhatnagar; Jeffrey Keefer; Emily A Barron-Casella; James F Casella; Michael R Debaun
Journal:  Br J Haematol       Date:  2013-08-16       Impact factor: 6.998

6.  Laboratory and Genetic Biomarkers Associated with Cerebral Blood Flow Velocity in Hemoglobin SC Disease.

Authors:  Rayra Pereira Santiago; Camilo Vieira; Corynne Stephanie Ahouefa Adanho; Sanzio Silva Santana; Caroline Conceição Guarda; Camylla Vilas Boas Figueiredo; Luciana Magalhães Fiuza; Thassila Nogueira Pitanga; Junia Raquel Dutra Ferreira; Milena Magalhães Aleluia; Rodrigo Mota Oliveira; Dalila Luciola Zanette; Isa Menezes Lyra; Marilda Souza Goncalves
Journal:  Dis Markers       Date:  2017-07-16       Impact factor: 3.434

Review 7.  Genetic, laboratory and clinical risk factors in the development of overt ischemic stroke in children with sickle cell disease.

Authors:  André Rolim Belisário; Célia Maria Silva; Cibele Velloso-Rodrigues; Marcos Borato Viana
Journal:  Hematol Transfus Cell Ther       Date:  2017-11-26

Review 8.  Sickle cell anaemia: progress in pathogenesis and treatment.

Authors:  Samir K Ballas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia.

Authors:  Roberta Faria Camilo-Araújo; Olga Maria Silverio Amancio; Maria Stella Figueiredo; Ana Carolina Cabanãs-Pedro; Josefina Aparecida Pellegrini Braga
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-09

10.  Comment on "Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia".

Authors:  Marilda Souza Goncalves
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.